Management of ascites due to gastrointestinal malignancy

被引:99
作者
Saif, Muhammad W. [1 ]
Siddiqui, Imran A. R. [1 ]
Sohail, Muhammad A. [1 ]
机构
[1] Yale Univ, Sch Med, Dept Med Oncol, New Haven, CT 06520 USA
关键词
LARGE-VOLUME PARACENTESIS; ENDOTHELIAL GROWTH-FACTOR; PERITONEOVENOUS SHUNTS; OVARIAN-CANCER; ABDOMINAL PARACENTESIS; SYMPTOMATIC ASCITES; CIRRHOSIS; PALLIATION; INHIBITOR; CARCINOMA;
D O I
10.4103/0256-4947.55167
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ascites is the pathological accumulation of fluid within the abdominal cavity. The most common cancers associated with ascites are adenocarcinomas of the ovary, breast, colon, stomach and pancreas. Symptoms include abdominal distension, nausea, vomiting, early satiety, dyspnea, lower extremity edema, weight gain and reduced mobility. There are many potential causes of ascites in cancer patients, including peritoneal carcinomatosis, malignant obstruction of draining lymphatics, portal vein thrombosis, elevated portal venous pressure from cirrhosis, congestive heart failure, constrictive pericarditis, nephrotic syndrome and peritoneal infections. Depending on the clinical presentation and expected survival, a diagnostic evaluation is usually indicated as it will impact both prognosis and the treatment approach. Key tests include serum albumin and protein and a simultaneous diagnostic paracentesis, checking ascitic fluid, WBCs, albumin, protein and cytology. Median survival after diagnosis of malignant ascites is in the range of 1 to 4 months; survival is apt to be longer for ovarian and breast cancers if systemic anti-cancer treatments are available.
引用
收藏
页码:369 / 377
页数:9
相关论文
共 55 条
[1]   ON THE TREATMENT AND PROGNOSIS OF MALIGNANT ASCITES - IS THE SURVIVAL-TIME DETERMINED WHEN THE ABDOMINAL PARACENTESIS IS NEEDED [J].
APPELQVIST, P ;
SILVO, J ;
SALMELA, L ;
KOSTIAINEN, S .
JOURNAL OF SURGICAL ONCOLOGY, 1982, 20 (04) :238-242
[2]   Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis [J].
Arroyo, V ;
Gines, P ;
Gerbes, AL ;
Dudley, FJ ;
Gentilini, P ;
Laffi, G ;
Reynolds, TB ;
RingLarsen, H ;
Scholmerich, J .
HEPATOLOGY, 1996, 23 (01) :164-176
[3]   Malignant ascites - New concepts in pathophysiology, diagnosis, and management [J].
Aslam, N ;
Marino, CR .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (22) :2733-2737
[4]  
Bar-Sela G, 2006, ANTICANCER RES, V26, P709
[5]  
Beattie GJ, 1998, CLIN CANCER RES, V4, P1899
[6]   Malignant ascites: Systematic review and guideline for treatment [J].
Becker, G ;
Galandi, D ;
Blum, HE .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (05) :589-597
[7]  
BEREK JS, 1985, CANCER TREAT REV, V12, P23
[8]   INTRAPERITONEAL THERAPY OF MALIGNANT ASCITES ASSOCIATED WITH CARCINOMA OF OVARY AND BREAST USING RADIOIODINATED MONOCLONAL ANTIBODY-2G3 [J].
BUCKMAN, R ;
DEANGELIS, C ;
SHAW, P ;
COVENS, A ;
OSBORNE, R ;
KERR, I ;
REED, R ;
MICHAELS, H ;
WOO, M ;
REILLY, R ;
LAW, J ;
BAUMAL, R ;
GROVES, E ;
MARKS, A .
GYNECOLOGIC ONCOLOGY, 1992, 47 (01) :102-109
[9]   Octreotide as an agent for the relief of malignant ascites in palliative care patients [J].
Cairns, W ;
Malone, R .
PALLIATIVE MEDICINE, 1999, 13 (05) :429-430
[10]   The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites [J].
Easson, Alexandra M. ;
Beziak, Andrea ;
Ross, Susan ;
Wright, Jim G. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (08) :2348-2357